| Features: |
| Dipyridamole is a medication primarily used for its antiplatelet and vasodilatory effects.(cardiovascular)
Dipyridamole is primarily known as a phosphodiesterase inhibitor and anti‐platelet agent. Mechanism: Dipyridamole inhibits phosphodiesterases (PDEs), enzymes that break down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cancer Relevance: Increased cyclic nucleotide levels can affect cell proliferation, apoptosis, and differentiation. Elevated cAMP, for example, may contribute to growth arrest or modify signaling cascades in certain cancer cells. • Dipyridamole has been observed in some studies to exert antioxidant effects. • There is evidence—albeit less definitive in some cases—that dipyridamole might influence mitochondrial function, potentially altering the balance between ROS production and detoxification. • By stabilizing mitochondrial membranes or affecting mitochondrial signaling pathways, dipyridamole could reduce the likelihood of excessive ROS generation. Current literature does not provide strong evidence that dipyridamole directly inhibits the mevalonate pathway?? A) Nucleoside Salvage Blockade -Tumors often rely on nucleoside salvage under stress. -Dipyridamole blocks nucleoside uptake → replication stress and DNA synthesis pressure, especially when de novo synthesis is compromised. B) Metabolic Stress & Redox Effects -Interferes with PPP/NADPH support in certain contexts. -Can sensitize cells to oxidative and metabolic stress, tipping stressed tumors toward death. C) Adenosine Signaling Modulation -By altering extracellular/intracellular adenosine handling, dipyridamole can modify immune and stress signaling in the tumor microenvironment (context-dependent). -Chemo-sensitizer (adjunct) Yes (experimental) -Chemopreventive candidate Yes (preclinical/observational) |
| Source: |
| Type: |
| Sterol Regulatory Element-Binding Protein 2 (SREBP-2) SREBP-2 is a key transcription factor that primarily regulates cholesterol biosynthesis and uptake. In recent years, its dysregulation has been linked to altered lipid metabolism within tumors, potentially affecting tumor growth, metastasis, and response to treatment. – SREBP-2) is a pivotal transcriptional factor in cholesterol metabolism. – SREBP-2 controls the transcription of genes involved in cholesterol biosynthesis and uptake (e.g., HMG-CoA reductase, LDL receptor). – Cancer cells may upregulate SREBP-2 as part of metabolic rewiring to meet the demands of rapid proliferation. – Elevated SREBP-2 expression has been observed in several tumor types, including prostate, breast, and hepatocellular carcinoma. – High expression levels are sometimes associated with aggressive tumor phenotypes, increased proliferative capacity, and a higher incidence of metastasis. • SREBP-2 plays a critical role in maintaining lipid homeostasis, and its dysregulation in cancer can contribute to tumor growth and aggressiveness. • Elevated SREBP-2 expression is generally associated with enhanced tumor cell proliferation, increased risk of metastasis, and in some instances, a poorer prognosis. |
| 4988- | ATV, | Dipy, | Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines |
| - | in-vivo, | Melanoma, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:293 Target#:1132 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid